SoftOx signs distribution agreement with VESO, one of Norway’s leading companies for Animal Health. The agreement opens a new and exciting market for SoftOx.
VESO, is Norway's leading supplier of vaccines and medicines for animal health. The agreement means that VESO will distribute SoftOx's new product line within disinfection and wound care in the animal health market. The total market for these types of products is approx. 100 million in Norway.
Distribution agreement including development opportunities.
SoftOx and VESO initially enter into a distribution agreement for new products that are ready for the market, but the agreement also covers products under development at SoftOx. The agreement confirms that the close cooperation with scientific institutions at the University of Copenhagen and Oslo creates new and exciting product opportunities within the wound area to avoid and treat bacterial infections.
Opens new market for SoftOx with a total value of NOK 6 billion The is our first commercial agreement within the animal health segment, and is a significant milestone for the company. The agreement opens up a new market for SoftOx, with a total market value of approx. 6 billion Norwegian kroner in Europe and the United States.
Importance of reducing antibiotic use in animal health
SoftOx's products aims to be an important step in reducing the use of antibiotics in both humans and animals.
About VESO
VESO www.veso.no is Norway's leading supplier of veterinary vaccines, pharmaceuticals and merchandise. The company has more than 30 years of experience in Animal Health.
About SoftOx:
SoftOx Solutions AS (SoftOx) is a Norwegian MedTech company established in 2012 and listed on Merkur, Oslo Stock Exchange (SOFTOX-ME). The Company’s proprietary technology is focused on developing antimicrobial products that do not contain classical antibiotics or induce microbial resistance, aiming to prevent and treat biofilm-associated infections, either as medical device or pharmaceutical products. SWIS, a medical device class III, is the Company’s first product reaching clinical phase. For more information about SoftOx